Table 3. Women with evidence of prior exposure evaluated for vaccine efficacy.

	Lehtinen et al (2012)[19]	The FUTURE II Study Group (2007a)[1]	Castellsagué et al 2011[15]	Joura et al (2007)[20]	Olsson et al (2009)[14]
TVC * included:		Combination of women enrolled in the TVC** of four individual trials:[12], [21]–[23]		Combination of women enrolled in the TVC** of three individual trials:[12], [21], [23]	Sub-population of 2617 women from three individual trials who were seropositive and DNA-negative to one or more vaccine HPV type(s) at day 1.[12], [21], [23]
HPV-naïve	¶	¶	¶	¶
Evidence of exposure to any high-risk or low-risk HPV type	¶	¶	¶	¶
Abnormal cervical cytology	¶	¶		¶
Prevalent cervical disease		¶
Prevalent anogenital disease				¶
TVC-naïve included:		Combination of women enrolled in the TVC-naïve of four individual trials:[12], [21]–[23]		Combination of women enrolled in the TVC-naïve of three individual trials:[12], [21], [23]
HPV-naïve	¶	¶		¶
Evidence of current exposure to any low-risk HPV type	¶
Evidence of past exposure to any non-vaccine HPV type	¶
Evidence of exposure to any non-vaccine HPV type		¶		¶
Abnormal cervical cytology		¶		¶
NRT for HPV-16/18 related outcomes included:
HPV-naïve			¶
Evidence of exposure to vaccine types 6/11 and any non-vaccine HPV type			¶
Derived sub-group of exposed women included:
HPV-16/18/31/33/35/39/45/51/52/56/58/59/66/68 DNA+ (and potentially sero+) or HPV-16/18 sero+	¶
HPV-6/11/16/18 DNA+ and/or sero+		¶		¶
HPV-16/18 DNA+ and/or sero+			¶
Abnormal cervical cytology	¶
Prevalent cervical disease		¶
Prevalent anogenital disease				¶
Number of women in derived sub-group:	6484	1117	143	643

*Women with a history of genital warts or warts at baseline were not included in the TVC.

**A TVC was not investigated in one individual RCT.[21] Outcomes for a TVC in this report were derived from the summary of participants excluded from analysis, extracting data specifically on women excluded from the TVC-naïve.